高血压、冠心病患者血小板微粒活化标记物CD62 p和PAC-1检测的临床意义

Detection of the Platelet Activation Markers CD62p and PAC-1 in Patients with Hypertension and Coronary Heart Disease

目的：探究高血压、冠心病患者血小板微粒活化标记物 CD62 p和 PAC-1检测的临床意义。方法选取大连医科大学附属第二医院2012年1月～9月住院确诊的高血压患者42例、冠心病患者46例，健康体检者30例为对照组，应用流式细胞术（flow cytometry，FCM）检测血小板表面活化标记物 CD62 p和 PAC-1的阳性百分率，观察高血压组、冠心病组和健康对照组之间，高血压组和冠心病组之间结果的差异。结果高血压组、冠心病组血小板活化标记物 CD62 p及 PAC-1的阳性百分率分别为36.36％±9.62％，7.18％±8.20％，42.74％±14.60％和8.81％±12.53％，均高于正常对照组26.82％±9.13％和1.09％±1.05％，差异有统计学意义（t＝4.150～5.853，P＜0.01）。冠心病组血小板活化标记物CD62p的阳性百分率为42.74％±14.60％，高于高血压组36.36％±9.62％，差异有统计学意义（t＝2.444，P＜0.05）。结论高血压、冠心病患者血小板活化程度明显增高，存在血栓前状态，对高血压、冠心病患者应定期监测上述指标，以便早期防治血栓栓塞性并发症的发生。

Objective To investigate the clinical significance of platelet activation markers CD62p and PAC-1 in patients with hypertension and coronary heart diease.Methods To select patients who were in the Second Affiliated Hospital of Dalian Medical University between January 2012 and September 2012,42 patients with hypertension,46 patients with coronary heart disease.Flow cytometry was used to test the positive percentage of the platelet surface activation markers CD62p and PAC-1 .To observe the difference among hypertension group,coronary heart disease group and health control group;hyper-tension and coronary heart disease group.Results The positive percentage of platelet activation markers CD62p and PAC-1 in hypertension （36.36±9.62,7.18±8.20）%,coronary heart disease group （42.74±14.60,8.81±12.53）% showed sta-tistically significant differences （t=4.150～5.853,P〈0.01）compared with healthy control group （26.82±9.13 ,1.09± 1.05）%.The positive percentage of CD62p in coronary heart disease group （42.74±14.60）% was also higher than that of hypertension （36.36±9.62）%,and the difference between them was of statistical significance （t=2.444,P〈0.05）.Con-clusion The hypertensive patients and coronary heart disease were in pre-thrombotic state,the activation of platelet increase significantly.Molecular markers should be measured in hypertensive patients and coronary heart disease for prevention and treatment of thrombotic disease complication.